We are live on ! Find out more
RVNC

Revance Therapeutics, Inc.
RVNC

Delisted

RVNC was delisted on the 5th of February, 2025.

Back to rankings

80 hedge funds and large institutions have $301M invested in Revance Therapeutics, Inc. in 2014 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 40 increasing their positions, 19 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

111% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 19

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

18% less funds holding

Funds holding: 98 → 80 (-18)

46% less capital invested

Capital invested by funds: $556M → $301M (-$255M)

67% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 27

Holders
80
Holders Change
-18
Holders Change %
-18.37%
% of All Funds
2.32%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
9
Increased
40
Reduced
19
Closed
27
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Franklin Resources
Franklin Resources
California
+$27.1M
2
ACH
ArrowMark Colorado Holdings
Colorado
+$7.01M
3
PHS
PFM Health Sciences
California
+$3.98M
4
AllianceBernstein
AllianceBernstein
Tennessee
+$3.69M
5
JP Morgan Chase
JP Morgan Chase
New York
+$3M

Top Sellers

Rank Fund Capital Flow
1
Jennison Associates
Jennison Associates
New York
-$21.4M
2
CCM
Camber Capital Management
Massachusetts
-$21.4M
3
VAM
Visium Asset Management
New York
-$12.3M
4
DM
Deerfield Management
New York
-$8.72M
5
DCM
Driehaus Capital Management
Illinois
-$5.02M
Name Holding Trade Value Shares
Change 		Change in
Stake
WAS
76
Winch Advisory Services
Wisconsin
$4K +$2.61K +100 +100%
BlackRock
77
BlackRock
New York
$3K – – –
Barclays
78
Barclays
United Kingdom
$2K -$48.7K -1,868 -94%
SM
79
Sabby Management
Florida
$1.85K +$745K +28,600 +43%
Manulife (Manufacturers Life Insurance)
80
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$109 +$31.3K +1,200 +27%
CCM
81
Camber Capital Management
Massachusetts
– -$21.4M -630,000 Closed
VAM
82
Visium Asset Management
New York
– -$12.3M -362,922 Closed
DM
83
Deerfield Management
New York
– -$8.72M -256,500 Closed
Zurich Cantonal Bank
84
Zurich Cantonal Bank
Switzerland
– -$4.42M -130,000 Closed
PC
85
Pier Capital
Connecticut
– -$3.64M -106,985 Closed
MCM
86
Moore Capital Management
New York
– -$3.4M -100,000 Closed
EI
87
EAM Investors
California
– -$1.79M -52,668 Closed
GPCM
88
Granite Point Capital Management
Massachusetts
– -$1.7M -50,000 Closed
GACM
89
Green Arrow Capital Management
New York
– -$1.7M -50,000 Closed
Schroder Investment Management Group
90
Schroder Investment Management Group
United Kingdom
– -$1.7M -50,000 Closed
PAM
91
Panagora Asset Management
Massachusetts
– -$1.26M -37,118 Closed
RFC
92
Russell Frank Company
Washington
– -$1.09M -35,173 Closed
EEG
93
E.E. Geduld
– -$850K -25,001 Closed
AII
94
AGF Investments Inc
Ontario, Canada
– -$850K -25,000 Closed
GTC
95
Ghost Tree Capital
New York
– -$680K -20,000 Closed
PG
96
PEAK6 Group
Illinois
– -$646K -19,000 Closed
Susquehanna International Group
97
Susquehanna International Group
Pennsylvania
– -$351K -10,331 Closed
Janney Montgomery Scott
98
Janney Montgomery Scott
Pennsylvania
– -$281K -8,250 Closed
RhumbLine Advisers
99
RhumbLine Advisers
Massachusetts
– -$213K -6,274 Closed
BJ
100
BlackRock Japan
Japan
– -$79K -2,332 Closed
1 2 3
4
5

RVNC Hedge Fund Activity: Q3 2014 in Review

80 of the 3,448 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q3 2014, worth a combined $301M — down 46% from $556M a quarter earlier.

Sellers outnumbered buyers: 27 funds closed out of RVNC and 9 opened new positions — a net loss of 18 holders — while 19 trimmed existing stakes and 40 added.

The largest buyer was Franklin Resources, adding an estimated $27.1M. The largest seller was Jennison Associates, cutting an estimated $21.4M.

  • 80 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q3 2014, down from 98 in Q2 2014.
  • Funds reported $301M of Revance Therapeutics, Inc. stock for Q3 2014, down 46% quarter-over-quarter.
  • 9 funds opened new Revance Therapeutics, Inc. positions in Q3 2014 and 27 closed out, a net change of -18 holders.
  • The largest Revance Therapeutics, Inc. buyer in Q3 2014 was Franklin Resources, an estimated $27.1M added.
  • The largest Revance Therapeutics, Inc. seller in Q3 2014 was Jennison Associates, an estimated $21.4M sold.

Based on aggregated 13F filings for Q3 2014.